Abbott Laboratories Corporation

Other

Central Glass Company, Limited

Abbott Laboratories & Central Glass Co Ltd

Christopher Bieniarz

Jeffrey B Huff

Michael J Cornwell

Douglas F Young

Keith R Cromack

Toshikazu Kawai

Earl R Speicher

Rajagopalan Raghavan

David Loffredo

Steve H Chang

Manami Kobayashi

Christopher J Welch

Kornepati V Ramakrishna

Denis R Henrard

Grady Barnes

Shuyen L Huang

Mazhar Husain

Zbigniew Skrzypczynski

Honorate A Stelmach

Maciej B Adamczyk

Michael D Fiechtner

Christopher Behme

Mohamed Shipchandler

Carol A Schlesinger

Fortuna Haviv

Mark R Pope

James D Ratajczyk

Seshagiri R Tata Venkata

Dominique Bridon

Wayne J Horng

J Christopher Welch

Amy Jo Sanders

Howard E Bond

Honorats A Stelmach

Mark Bures

The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.

Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

The invention relates to a bioerodible polymeric composition, a method of making such a composition, and a controlled delivery device comprising the composition.

Polymeric compositions and a method of making the same

A method for fluoromethylation of a halogenated alcohol. The method includes refluxing a halogenated alcohol with a dihalomethane under basic conditions in a first solvent to form a halomethyl ether and fluorinating the halomethyl ether in the presence of a fluorinating agent.

Synthetic method for fluoromethylation of halogenated alcohols

A method for fluoromethylation of an alcohol via halogenative decarboxylation. The method includes the step of reacting an alcohol of the formula R,C(CX,),OH with an alpha-haloester of the formula X,CH,CO,R,to form an alpha-alkoxy ester, wherein R,is selected from the group consisting of hydrogen and alkyl groups, wherein R,is selected from the group consisting of hydrogen and alkyl groups, wherein X, at each occurrence, is independently selected from the group consisting of hydrogen, bromine, fluorine, and chlorine, and wherein X,is selected from the group consisting of bromine and chlorine. The resulting alpha-alkoxy ester is saponified to form an alpha-alkoxy acid which is heated at reflux with lead tetraacetate and a chlorinating agent to form a chloride compound of the formula R,C(CX,),OCH,Cl. The chloride compound is converted to a fluoride compound of the formula R,C(CX,),OCH,F with a fluorinating agent.

Method for fluoromethylation of alcohols via halogenative decarboxylation

A method for fluoromethylating halogenated alcohols. The method includes the step of providing an alpha-halogenated alcohol of the formula R,C(CX,),OH, wherein R,is selected from the group consisting of hydrogen and alkyl groups. The alpha-halogenated alcohol is reacted with a first compound of the formula CH,(OR,),in the presence of an acid catalyst to form an acetal. The resulting acetal is then chlorinated with a chlorinating agent to form a chloride compound of the formula R,C(CX,),OCH,Cl. The chloride compound is then converted to a fluoride compound of the formula R,C(CX,),OCH,F using a fluorinating agent.

Synthetic method for the fluoromethylation of alcohols

The present invention provides crosslinking, conjugating and reducing agents which are functional with at least one phosphorothioate monoester group (--SPO.sub.3.sup.--2). Crosslinking and conjugation methods as well as solid phase reagents and conjugates which are useful in immunoassays are also provided. Crosslinking and conjugating agents of the invention generally comprise a compound corresponding to the formula (I), shown below, wherein n at least 1 and Q is a straight or branched monomer, polymer or oligomer having an average molecular weight between about 200 and about 1,000,000. Additionally, when n is 1, Q comprises at least 1 additional reactive functionality.

Phosphatase activated crosslinking conjugating and reducing agents;

A method for synthesizing fluoromethyl-1,1,1,3,3,3-hexafluoroisopropyl ether. The method includes the step of combining in the presence of aluminum trichloride a quantity of hexafluoroisopropanol and a quantity of either 1,3,5-trioxane or paraformaldehyde to produce sevochlorane. The resulting sevochlorane is then combined with an alkali metal fluoride to produce fluoromethyl-1,1,1,3,3,3-hexafluoroisopropyl ether.

Method for synthesizing sevoflurane and an intermediate thereof

The present invention provides crosslinking, conjugating and reducing agents which are functional with at least one phosphorothioate monoester group (--SPO.sub.3.sup.-2). Crosslinking and conjugation methods as well as solid phase reagents and conjugates which are useful in immunoassays are also provided. Crosslinking and conjugating agents of the invention generally comprise a compound corresponding to the formula (I), shown below, wherein n at least 1 and Q is a straight or branched monomer, polymer or oligomer having an average molecular weight between about 200 and about 1,000,000. Additionally, when n is 1, Q comprises at least 1 additional reactive functionality.

Phosphatase activated crosslinking, conjugating and reducing agents;

Intercalator compounds of formula I-T.sub.m as defined herein are provided which are comprised of intercalator moieties, or substituted intercalator moieties, having one or more functionalized chains, or moieties, and which compounds provide a high affinity for binding to the DNA molecule and show reduced self-quenching, while providing superior transport kinetics. The compounds have been found to provide enhanced fluorescence when bound to a DNA molecule within a fluorescent flow cytometry environment which is about eight to ten times brighter in fluorescence than 'bis' structure conventional intercalating agents and other known intercalating agents utilized in flow cytometry environment.

Intercalators having affinity for DNA and methods of use

Fluorescent conjugates suitable for use in flow cytometry and other biological applications. The fluorescent conjugates comprise an antibody having a polymeric dye bound thereto. The polymeric dye is preferably enhanced by a hydrophobic and conformationally restrictive moiety either bound thereto or in close association therewith. The hydrophobic and conformationally restrictive moiety is preferably derived from a cyclodextrin. The polymeric dye comprises a polymeric entity having signal-generating groups, such as aminostyryl pyridinium dye residues attached thereto. The fluorescent conjugates exhibit exceptional stability characteristics and avoid many of the problems of energy transfer, bio-conjugability, and solubility.

Polymeric fluorophores enhanced by moieties providing a hydrophobic and

Fluoroether compositions and methods for inhibiting their degradation in

Intercalator compounds are provided which are comprised of intercalator moieties, or substituted intercalator moieties, having one or more functionalized chains, or moieties, and which compounds provide a high affinity for binding to the DNA molecule and show reduced self-quenching, while providing superior transport kinetics. The compounds have been found to provide enhanced fluorescence when bound to a DNA molecule within a fluorescent flow cytometry environment which is about eight to ten times brighter in fluorescence than 'bis' structure conventional intercalating agents and other known intercalating agents utilized in flow cytometry environment.

Growing community of inventors

Highland Park, IL, United States of America

Christopher Bieniarz